Miami Cancer Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Miami FL United States (2017)

Organization Overview

First Clinical Trial
2017
NCT02525653
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Miami Cancer Institute | University of Pisa / Miami Cancer Institute

Active Ingredients

Drugs in Phase 3 Trials (2)

bevacizumab (avastin) (1 trial)

durvalumab (imfinzi) (1 trial)

Drugs in Phase 2 Trials (5)

azeliragon (1 trial)

cabozantinib (cometriq) (1 trial)

gemcitabine (gemzar) (2 trials)

paclitaxel (taxol) (2 trials)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (1)

t-cell depleted lymphocytes (1 trial)

Drugs in Other Trials (1)

pegph20 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 9